1. Home
  2. RHI vs HAE Comparison

RHI vs HAE Comparison

Compare RHI & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Robert Half Inc.

RHI

Robert Half Inc.

HOLD

Current Price

$24.05

Market Cap

2.6B

ML Signal

HOLD

Logo Haemonetics Corporation

HAE

Haemonetics Corporation

HOLD

Current Price

$59.48

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RHI
HAE
Founded
1948
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.6B
IPO Year
1994
1996

Fundamental Metrics

Financial Performance
Metric
RHI
HAE
Price
$24.05
$59.48
Analyst Decision
Hold
Buy
Analyst Count
6
9
Target Price
$30.33
$85.38
AVG Volume (30 Days)
2.6M
600.7K
Earning Date
04-22-2026
05-07-2026
Dividend Yield
9.49%
N/A
EPS Growth
N/A
44.54
EPS
1.33
2.46
Revenue
$5,378,506,000.00
$910,373,000.00
Revenue This Year
$1.27
N/A
Revenue Next Year
$5.95
$5.31
P/E Ratio
$18.68
$23.74
Revenue Growth
N/A
N/A
52 Week Low
$21.83
$47.32
52 Week High
$51.55
$87.32

Technical Indicators

Market Signals
Indicator
RHI
HAE
Relative Strength Index (RSI) 47.13 51.95
Support Level $22.08 $48.47
Resistance Level $25.19 $66.86
Average True Range (ATR) 1.16 1.73
MACD 0.20 0.42
Stochastic Oscillator 54.29 80.92

Price Performance

Historical Comparison
RHI
HAE

About RHI Robert Half Inc.

Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry.

About HAE Haemonetics Corporation

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Share on Social Networks: